CORA RIDENOUR: Open Payments
NPI 1750168076 · SAN DIEGO, CA. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,148 in 269 payments from 20 companies in 2025. Trend: 2023 $393 · 2024 $4,234 · 2025 $5,148
Food & beverage: $5,056Education: $92
| Company | Payments | Amount |
|---|---|---|
| ABBVIE INC. | 53 | $1,246 |
| Salix Pharmaceuticals, a division of Bausch Health US, LLC | 96 | $1,193 |
| Janssen Biotech, Inc. | 21 | $548 |
| Ardelyx, Inc. | 17 | $338 |
| QOL Medical, LLC | 12 | $310 |
| Takeda Pharmaceuticals U.S.A., Inc. | 18 | $286 |
| Alnylam Pharmaceuticals Inc. | 3 | $178 |
| Regeneron Healthcare Solutions, Inc. | 8 | $169 |
| PFIZER INC. | 13 | $158 |
| GENZYME CORPORATION | 4 | $123 |
Products named: XIFAXAN, RINVOQ, TREMFYA, IBSRELA, SKYRIZI, Sucraid, DUPIXENT, ENTYVIO.
Industry payments across CA — which companies pay providers there.
